As of close of business last night, Boston Scientific Corporation’s stock clocked out at $51.50, down -4.06% from its previous closing price of $53.68. In other words, the price has decreased by -$2.18 from its previous closing price. On the day, 12850805 shares were traded. BSX stock price reached its highest trading level at $53.58 during the session, while it also had its lowest trading level at $51.38.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
To gain a deeper understanding of BSX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 129.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 61.63. For the most recent quarter (mrq), Quick Ratio is recorded 0.90 and its Current Ratio is at 1.40. In the meantime, Its Debt-to-Equity ratio is 0.50 whereas as Long-Term Debt/Eq ratio is at 0.48.
Upgrades & Downgrades
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 16 when Fitzgerald Joseph Michael sold 63,339 shares for $53.60 per share. The transaction valued at 3,394,856 led to the insider holds 213,859 shares of the business.
Carruthers Wendy sold 11,671 shares of BSX for $624,333 on May 15. The EVP, Human Resources now owns 78,110 shares after completing the transaction at $53.49 per share. On May 02, another insider, Thepaut Eric Francis Yves, who serves as the EVP & Pres, Eur, Mid-East, Afr of the company, sold 83,401 shares for $52.49 each. As a result, the insider received 4,377,543 and left with 12,269 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BSX now has a Market Capitalization of 73.45B and an Enterprise Value of 81.80B. As of this moment, Boston’s Price-to-Earnings (P/E) ratio for their current fiscal year is 87.88, and their Forward P/E ratio for the next fiscal year is 23.24. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 7.22. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.65 while its Price-to-Book (P/B) ratio in mrq is 4.14. Its current Enterprise Value per Revenue stands at 6.27 whereas that against EBITDA is 32.81.
Stock Price History:
Over the past 52 weeks, BSX has reached a high of $54.17, while it has fallen to a 52-week low of $34.98. The 50-Day Moving Average of the stock is 51.10, while the 200-Day Moving Average is calculated to be 45.62.
It appears that BSX traded 9.06M shares on average per day over the past three months and 8.34M shares per day over the past ten days. A total of 1.44B shares are outstanding, with a floating share count of 1.43B. Insiders hold about 0.20% of the company’s shares, while institutions hold 94.60% stake in the company. Shares short for BSX as of Apr 27, 2023 were 17.97M with a Short Ratio of 17.97M, compared to 15.16M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 1.25% and a Short% of Float of 1.25%.
As of right now, 25 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.49 for the current quarter, with a high estimate of $0.5 and a low estimate of $0.48, while EPS last year was $0.44. The consensus estimate for the next quarter is $0.48, with high estimates of $0.5 and low estimates of $0.47.
Analysts are recommending an EPS of between $2 and $1.93 for the fiscal current year, implying an average EPS of $1.95. EPS for the following year is $2.22, with 27 analysts recommending between $2.32 and $2.15.
In the current quarter, 21 analysts expect revenue to total $3.5B. It ranges from a high estimate of $3.56B to a low estimate of $3.48B. As of the current estimate, Boston Scientific Corporation’s year-ago sales were $3.24B, an estimated increase of 7.90% from the year-ago figure. For the next quarter, 21 analysts are estimating revenue of $3.44B, an increase of 8.40% over than the figure of $7.90% in the same quarter last year. There is a high estimate of $3.51B for the next quarter, whereas the lowest estimate is $3.35B.
A total of 28 analysts have provided revenue estimates for BSX’s current fiscal year. The highest revenue estimate was $14.09B, while the lowest revenue estimate was $13.73B, resulting in an average revenue estimate of $13.93B. In the same quarter a year ago, actual revenue was $12.68B, up 9.90% from the average estimate. Based on 28 analysts’ estimates, the company’s revenue will be $15.05B in the next fiscal year. The high estimate is $15.35B and the low estimate is $14.72B. The average revenue growth estimate for next year is up 8.00% from the average revenue estimate for this year.